Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
U-Neuron BiomedicalROCO:6973 +4.68%32 Gross Margin % is 63.77% as of Jun. 2026, which is 21% below its 10-year median of 80.56. GuruFocus rates ROCO:6973 with a GF Score™ of 32/100 and a GF Value™ of NT$70.22 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 735 Biotechnology companies, U-Neuron Biomedical ranks better than 54.69% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
U-Neuron Biomedical had a gross margin of 63.77% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
U-Neuron Biomedical Gross Margin % Related Terms
U-Neuron Biomedical Gross Margin % Historical Data
* Premium members only.
The historical data trend for U-Neuron Biomedical's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6973 vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, U-Neuron Biomedical's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
U-Neuron Biomedical Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, U-Neuron Biomedical's Gross Margin % distribution charts can be found below:
* The bar in red indicates where U-Neuron Biomedical's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
U-Neuron Biomedical (ROCO:6973) has a Gross Margin % of 63.77% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on U-Neuron Biomedical and its competitors. This is 21% below median its historical median of 80.56. Over the past decade, U-Neuron Biomedical's Gross Margin % has ranged from 65.61 to 84.21. According to the industry distribution chart, U-Neuron Biomedical ranks #333 out of 735 companies in the Biotechnology industry, placing it in the top 45.3%.
Is U-Neuron Biomedical's Gross Margin % too high?
U-Neuron Biomedical's current Gross Margin % of 63.77% is 21% below median its 10-year median of 80.56. Over the past 10 years, this metric has ranged from a low of 65.61 to a high of 84.21. The Biotechnology industry median Gross Margin % is 60.91. U-Neuron Biomedical's value of 63.77% is 4.7% above this industry median. Based on the distribution chart, U-Neuron Biomedical ranks #333 out of 735 companies in the Biotechnology industry, which is above the industry midpoint. Overall, U-Neuron Biomedical has a GF Score™ of 32/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does U-Neuron Biomedical's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, U-Neuron Biomedical ranks #333 out of 735 companies for Gross Margin %. This puts U-Neuron Biomedical in the upper half of its industry. The industry median Gross Margin % is 60.91. U-Neuron Biomedical's value of 63.77% is 4.7% above this benchmark. Historically, U-Neuron Biomedical's own Gross Margin % has ranged from 65.61 to 84.21 over the past decade. While the company's 10-year median is 80.56 vs. the industry median of 60.91, U-Neuron Biomedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. U-Neuron Biomedical's current Gross Margin % of 63.77% is 4.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on U-Neuron Biomedical and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. U-Neuron Biomedical's current Gross Margin % is 63.77%, which is 21% below median its own 10-year median of 80.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is U-Neuron Biomedical stock overvalued right now?
Based on GuruFocus' analysis, U-Neuron Biomedical (ROCO:6973) is currently considered Possible Value Trap. The stock's GF Value™ is NT$70.22, compared to a current price of NT$41.35 — trading 41.1% below its estimated fair value. The current Gross Margin % is 63.77%, which is 21% below median its 10-year median of 80.56 and 4.7% above the Biotechnology industry median of 60.91. U-Neuron Biomedical's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For U-Neuron Biomedical (ROCO:6973), the current Gross Margin % is 63.77% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is U-Neuron Biomedical (ROCO:6973) Overvalued in 2026?
Based on GuruFocus' analysis, U-Neuron Biomedical stock appears to be undervalued.
The current stock price of NT$41.35 is trading 41.1% below its estimated GF Value™ of NT$70.22.
GuruFocus considers U-Neuron Biomedical to be Possible Value Trap.
Key valuation signals for ROCO:6973:
Gross Margin %: 63.77% (21% below median its 10-year median of 80.56)
GF Value™: NT$70.22 vs. price of NT$41.35 (41.1% below fair value)
Industry Position: 4.7% above the Biotechnology median (#333 of 735)
No single metric tells the full story. See the ROCO:6973 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
U-Neuron Biomedical Inc is engaged in research and development of stem cell storage & separation technology, and treatment application technology. It has patent on the Technology of Culture and Isolation of Amniotic Fluid Stem Cell.
32GF Score
Get the complete analysis for ROCO:6973
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6973 has been successfully added to your 
